Using Echinocandins for Neonatal Candidiasis
Author Information
Author(s): Dermitzaki Niki, Balomenou Foteini, Gialamprinou Dimitra, Giapros Vasileios, Rallis Dimitrios, Baltogianni Maria
Primary Institution: Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, Greece
Hypothesis
Echinocandins may be effective alternatives for treating invasive Candida infections in neonates.
Conclusion
Echinocandins, particularly micafungin, are promising antifungal agents for treating neonatal candidiasis, especially when conventional treatments are ineffective.
Supporting Evidence
- Echinocandins are effective against a wide range of Candida strains.
- Micafungin is the only echinocandin approved for use in neonates.
- Echinocandins have a favorable safety profile compared to conventional antifungals.
- Resistance to first-line antifungals like fluconazole is increasing in neonates.
- High doses of micafungin may be necessary for effective treatment in cases of CNS involvement.
Takeaway
Echinocandins are special medicines that can help sick babies fight off certain infections caused by fungi, especially when other medicines don't work.
Methodology
The authors reviewed existing literature on the use of echinocandins in neonates, focusing on pharmacokinetics, efficacy, and safety.
Potential Biases
Potential bias due to the exclusion of non-English articles.
Limitations
The review is narrative and may be subject to selection bias due to non-standardized literature search methods.
Participant Demographics
The review discusses neonates, particularly those with low birth weight and invasive candidiasis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website